The Novartis company was founded in 1996, as a result of the merger of the two companies Siba-Geigi and Sandoz. Novartis and its predecessor companies have a rich history in the field of production of innovative products, which has more than two hundred and fifty years.
These companies are united by a common desire to develop and launch completely new products on the pharmacological market that can support the development of mankind with the help of sharp breakthroughs in science and healthcare. This is the trait that continues to exist in Novartis to this day.
Novartis in Russia
The Novartis group of companies in Russia offers drugs for solving healthcare issues that meet completely new needs of society and patients. The company has a diversified portfolio (this is a combination of assets where no paper is dominant). And also currently occupies a leading position in the Russian pharmaceutical market in the production of nanopreparations, as well as high-quality generics and over-the-counter medicines, medical equipment and medicines for preserving vision.
The development of the company in Russia has more than one hundred and twenty years. Since the opening of the first pharmaceutical company in the late nineteenth century and to the present, the company has been a reliable partner of Russia in healthcare and improving patient access to high-quality drugs from Novartis.
The number of employees exceeds eight hundred people. The company has offices in the following cities: Moscow, St. Petersburg, Yekaterinburg, Novosibirsk, Kazan and Rostov-on-Don.
Tasks of Novartis
The manufacturer relies on scientific development and is focused on people. Novartis strives to occupy a leading position in the well-developing sectors of medicine and healthcare. After the transformation, the Novartis group of companies focused on three key areas in which they occupy more powerful positions at the world level and which provide uninterrupted innovative opportunities: the manufacture and sale of pharmaceutical drugs, as well as ophthalmic products and analogues. This approach helps maximize the power of the company.
Innovative drugs
The Pharmaceuticals Division is developing the latest patented, highly effective drugs for patients and healthcare professionals. The company carries out advanced development and production of pharmaceuticals from Novartis in oncology, as well as for first aid.
"Femara"
An antitumor drug that is used to treat breast cancer in postmenopausal women. The drug has an antiestrogenic effect, selectively reduces the rate of estrogen production, which is carried out using highly specific competitive binding to heme cytochrome P450.
In peripheral and tumor tissues, it blocks the formation of estrogen. The hormone produced in women in the ovaries during the postmenopausal period is formed, as a rule, with the participation of the aromatase enzyme, which converts androgens that form in the adrenal glands.
When using the drug daily 0.1–5 milligrams of letrozole, a decrease in the plasma content of estradiol, as well as estrone sulfate and estrone in the blood, is ninety-five percent of the initial level.
Throughout therapy, there is a limitation in the production of estrogen. The use of Femara in pharmacological dosages does not lead to an imbalance in the formation of steroid hormones in the adrenal glands; subsequently, the test with adrenocorticotropic hormone failed to produce cortisol or aldosterone.
The blockade of the biological synthesis of estrogens to the accumulation of androgens, which are considered precursors of estrogens, does not occur. Also during treatment, a change in the plasma contents of the gonadotropin hormone of the anterior pituitary gland and peptide hormone in the blood. During the use of Femara, the frequency of osteoporosis increases slightly, while the frequency of bone fractures does not change.
Gleevec
This is the most famous drug from the company "Novartis", which is used in oncology. The use of the active substance (imatinib) in the treatment of patients with metastatic or inoperable malignant gastrointestinal neoplasms leads to an increase in survival without disease symptoms (twenty-one months) and overall survival of patients (forty-eight months).
In adjuvant treatment of the most common mesenchymal tumor of the stomach and intestines, the probability of recurrence of the disease decreased by eighty-nine percent throughout the year, and survival without signs of the disease increased (placebo - twenty months, imatinib - thirty-eight months). The result of this treatment over the course of three years has been a significant increase in overall survival.
Novartis: drugs for neurology
Medicines that are often used for neurological diseases:
- Sirdalud.
- Exelon.
- Tavegil.
- "Anafranil."
- Tegretol.
- Voltaren.
- Leponex.
Next, the most effective drugs will be considered.
Sirdalud
The drug of the Novartis company belongs to the group of muscle relaxants of the central effect. The active substance is tizanidine. The active component acts on certain areas of the spinal cord by activating presynaptic alpha2-nerve endings, which leads to inhibition of the irritating amino acids that stimulate receptors.
This causes the suppression of polysynaptic transmission of stimulation at the level of intermediate neurons that are in the spinal cord. Since increased muscle tone is caused precisely by such a mechanism, when it is inhibited, a decrease in muscle tone is observed.
In addition to the muscle relaxant effect, the active substance is also characterized by a central analgesic effect of moderate severity. The increased effectiveness of the drug has been confirmed both in chronic spasms of cerebral and spinal origin, and in muscle cramps, which are accompanied by acute pain.
Exelon
According to the instructions for use, Exelon is considered a selective inhibitor of Alzheimer's disease, and dementia in Parkinson's disease. The use of the drug inhibits the destruction of the main neurotransmitter, which is responsible for neuromuscular transmission to the parasympathetic nervous system.
In addition, the active substance of the drug increases the concentration of acetylcholine in the cerebral cortex, which significantly improves the transmission of excitation in the cholinergic synapse. The drug, according to patients, has a positive effect on a decrease in cognitive functions provoked by acetylcholine deficiency, in particular with insanity caused by Alzheimer's or Parkinson's disease. In addition, there is evidence that the use of Exelon slows the formation of amyloid plaques, which are considered the main pathological symptom of Alzheimer's disease.
Analogs
Medicines from the Novartis company have substitutes in the spectrum of action, for example, Russian generics, which are no less effective.
For example, with oncology, the following drugs are prescribed:
- Cyclophosphamide.
- "Cyclophosphamide".
- "Cytoxan".
- "Endoscan."
- "Ifosfamide".
- Gemcitabine.
- Gemzar.
- "Cytohem."
- Hydroxycarbamide.
- Paclitaxel
- Goserelin.
- "Tiotepa."
- Tamoxifen.
- "Letromara".
- "Methotrexate".
- Epirubicin.
- Trastuzumab.
The drug from malignant neoplasms of the uterus:
- "Chlorambucil."
- "Cyclophosphamide".
- "Dacarbazine".
- "Methotrexate".
Cervical Cancer Medication:
- Cyclophosphamide.
- "Ifosfamide".
- Pertuzumab.
- Xeloda.
Ovarian Cancer Medication:
- Cisplatin.
- "Cytoforsfan."
- Melphalan.
- "Fluorouracil".
- "Chlorambucil."
Bone Cancer Drug :
- "Ifosfamide".
- "Cabroplatinum."
- "Cyclophosphamide".
Blood Cancer Medicine:
- "Cytarabine".
- Ibrutinib.
- "Doxorubicin."
- Idarubicin.
- "Fludarabine."
Reviews
Reviews about the drugs "Novartis", due to the specifics of their use, are few, but, as a rule, are positive. According to patients who took the medicines of this manufacturer, medicines fully cope with their purpose and help alleviate the symptoms of existing diseases.
In fairness, it should be noted that absolutely all people undergoing treatment with Novartis drugs observed certain adverse reactions, and in rare situations, these effects took on such a format that they required the cessation of therapy or the transfer of a person to reduced dosages.